LifeVantage (LFVN) Expected to Announce Quarterly Earnings on Wednesday

LifeVantage (NASDAQ:LFVN) is expected to announce its earnings results after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $67.41 million for the quarter. Individual interested in participating in the company’s earnings conference call can do so using this link.

LifeVantage Price Performance

Shares of NASDAQ LFVN opened at $21.16 on Monday. LifeVantage has a 1-year low of $5.22 and a 1-year high of $27.38. The business’s 50 day moving average is $18.62 and its two-hundred day moving average is $13.32. The stock has a market capitalization of $265.03 million, a P/E ratio of 66.13 and a beta of 0.82.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on LFVN. Craig Hallum initiated coverage on LifeVantage in a research report on Tuesday, January 14th. They set a “buy” rating and a $35.00 target price on the stock. Lake Street Capital initiated coverage on shares of LifeVantage in a research report on Thursday, December 19th. They set a “buy” rating and a $26.00 price objective on the stock.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.